Cough syrup deaths: SC agrees to hear PIL seeking CBI probe, safety review

The plea seeks a court-monitored probe into the incidents and urges the constitution of a National Judicial Commission or Expert Committee headed by a retired Supreme Court judge

Supreme Court, SC
The bench agreed to hear the plea on October 10. (Photo:PTI)
Press Trust of India New Delhi
2 min read Last Updated : Oct 09 2025 | 11:48 AM IST

The Supreme Court agreed to hear on Friday a PIL seeking inquiry and systemic reform in drug safety mechanisms in the wake of deaths of children in Madhya Pradesh and Rajasthan allegedly due to consumption of toxic cough syrups.

A bench comprising Chief Justice B R Gavai and Justices Ujjal Bhuyan and K Vinod Chandran took note of the submissions of PIL petitioner and lawyer Vishal Tiwari that the plea needed an urgent hearing.

The bench agreed to hear the plea on October 10.

The plea seeks a court-monitored probe into the incidents and urges the constitution of a National Judicial Commission or Expert Committee headed by a retired Supreme Court judge.

The PIL requests that all pending FIRs and investigations concerning the deaths of children caused by toxic cough syrups across states be transferred to the CBI.

It seeks a probe under the supervision of a retired Supreme Court judge to ensure fairness and uniformity.

The petition contends that separate state-level investigations have led to fragmented accountability, enabling repeated lapses that allow hazardous formulations to reach the market.

The petition comes amid reports from Madhya Pradesh and Rajasthan, where several children died allegedly after consuming a particular kind of cough syrup.

The plea seeks court's direction to the central government to identify the regulatory failures that allowed substandard medicines to reach the market.

It also urged the court to mandate toxicological testing of all suspect products through NABL-accredited laboratories before any further sale or export is permitted.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Cough syrupSupreme CourtCBI

First Published: Oct 09 2025 | 11:48 AM IST

Next Story